New allosteric inhibitors of cholesterol synthesis – an alternative to statins?

29-Aug-2013 - Israel

Researchers in Israel have identified a new catalytic anti-oxidant that could be a promising alternative to statins – the most prescribed cholesterol-lowering drugs in the world.

Statins reduce cholesterol levels in the body by acting as competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase – the enzyme that catalyses cholesterol biosynthesis. But some patients don’t respond to statins and catalytic anti-oxidants have an advantage over statins: in their dual mode of action, they also reduce free radicals in the body.

The scientists showed that the catalytic antioxidant, Fe-1, and its analogues, inhibit HMG-CoA reductase in a different way to statins. They propose that the amphipolar nature of the drug macrocycles is important for binding to an allosteric site of HMG-coA reductase and inhibiting the enzyme’s catalytic activity.

Original publication

Other news from the department science

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?